Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2007, vol. 16, nr 4, July-August, p. 589–592

Publication type: letter to editor

Language: English

The Challenge of Individualizing Genetic Counselling in Cancer Families – a Case Report

Poradnictwo genetyczne w nietypowych przypadkach rodzinnego występowania nowotworów – opis przypadku

Karolina A. Pesz1,, Alicja Trusewicz1,, Ryszard Ślęzak1,, Maria M. Sąsiadek1,

1 Department of Genetics, Silesian Piasts University of Medicine in Wrocław, Poland

References (13)

  1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55, 74–108.
  2. American College of Medical Genetics Foundation: Genetic Susceptibility to Breast and Ovarian Cancer: Assessment, Counseling and Testing Guidelines. 1999, http://www.health.state.ny.us/nysdoh/cancer/obcancer/ /contents.htm
  3. Pharoah PD, Day NE, Duffy S, Easton DF, Ponder BA: Family history and the risk of breast cancer: a systematic review and meta−analysis. Int J Cancer 1997, 71, 800–809.
  4. Jakubowska A, Nej K, Huzarski T, Scott RJ, Lubinski J: BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer 2002, 87, 888–891.
  5. Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymanska A, Szymanska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubinski J: CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004, 75, 1131–1135.
  6. Cybulski C, Gorski B, Debniak T, Gliniewicz B, Mierzejewski M, Masojc B, Jakubowska A, Matyjasik J, Złowocka E, Sikorski A, Narod SA, Lubinski J: NBS1 is a prostate cancer susceptibility gene. Cancer Res 2004, 64, 1215–1219.
  7. Huzarski T, Lener M, Domagala W, Gronwald J, Brylski T, Kurzawski G, Suchy J, Chosia M, Woyton J, Ucinski M, Narod SA, Lubinski J: The 3020insC allele of NOD2 predisposes to early−onset breast cancer. Brest Cancer Res Treat 2005, 89, 91–93.
  8. Gorski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Pluzanska A, Bebenek M, Fischer−Maliszewska L, Grzybowska E, Narod SA, Lubinski J: Founder mutations in the BRCA1 gene in Polish families with breast−ovarian cancer. Am J Hum Genet 2000, 66, 1963–1968.
  9. Antoniou AC, Pharoach PDP, Narod S, Risch HA et al.: Breast and ovarian cancer risk to carriers of the BRCA1 5382incC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 2005, 42, 602–603.
  10. Janiszewska H, Haus O, Laude−Świeciak A, Pasińska M, Laskowski R, Szymański W, Górski B, Lubiński J: Frequency of tree BRCA1 gene founder mutations in breast/ovarian cancer families from the Pomerania−Kujawy region of Poland. Clin Genet 2003, 64, 502–508.
  11. Cheung P, Chan R, Wong BYL, Ozcelik H, Cole DEC: Simple and Rapid Detection of BRCA1 and BRCA2 Mutations by Multiplex Mutagenically Separated PCR. Clin Chem 1999, 45, 1285–1287.
  12. Crane AM, Bradbury L, van Heel DA, McGovern DP, Brophy S, Rubin L, Siminovitch KA, Wordsworth BP, Calin A, Brown MA: Role of NOD2 Variants in Spondylarthritis. Arhritis Rheum 2002, 46, 1629–1633.
  13. Dębniak T, Górski B, Cybulski C, Jakubowska A, Kurzawski G, Lener M, Mierzejewski M, Masojć B, Mędrek K, Kładny J, Załuga E, Maleszka R, Chosia M, Lubiński J: Germline 657 del5 mutation in the NBS1 gene in patients with malignant melanoma of the skin. Melanoma Res 2003, 13, 356–370.
© Wroclaw Medical University